Pelthos Therapeutics at the Annual Healthcare Conference
DURHAM, N.C. — Pelthos Therapeutics Inc. (NYSE American: PTHS), a dedicated biopharmaceutical company focused on developing innovative therapies for patients, is poised to highlight its contributions at the upcoming Piper Sandler 37th Annual Healthcare Conference. The event will take place on December 4 at The Lotte New York Palace, and Scott Plesha, the CEO of Pelthos, is set to engage in a fireside chat at 9:30 a.m. Eastern Time.
Fireside Chat Details
This is an exciting opportunity for institutional investors to gain insights directly from Mr. Plesha regarding the company's mission and goals. Investors attending the conference in person are encouraged to arrange one-on-one meetings through their Piper Sandler representatives. This interaction will provide a platform to discuss Pelthos' strategic vision and existing innovations in the biopharmaceutical landscape.
Webcast Opportunity for Remote Attendees
For those who cannot attend the conference live, Pelthos is offering a web streaming option. A live broadcast of the fireside chat will be accessible on Pelthos's News & Events page shortly after the event. This arrangement ensures that even remote investors can be a part of the conversation surrounding the latest advancements in Pelthos' therapeutic developments.
Focus on Patient-Centric Therapeutics
Pelthos Therapeutics is committed to addressing unmet patient needs through its innovative approach to biopharmaceuticals. Key among its product line is ZELSUVMI™ (berdazimer) topical gel, which is designed for the treatment of molluscum contagiosum. Approved by the U.S. Food and Drug Administration recently, ZELSUVMI represents a significant stride in offering effective solutions for conditions that have long been overlooked.
Commitment to Innovation
Pelthos' approach is not just about providing a product; it's about transforming lives through science and innovation. The company’s dedication to creating safe, efficacious treatments exemplifies its commitment to patients who often struggle with treatment options. The introduction of ZELSUVMI demonstrates Pelthos' vision of bridging the gap in therapeutic interventions.
About Pelthos Therapeutics
Pelthos Therapeutics stands out in the biopharmaceutical sector due to its unwavering focus on creating revolutionary therapies aimed at improving patient outcomes. With a roster of promising products and a commitment to clinical excellence, Pelthos is redefining treatment paradigms for various conditions. Their innovative solutions stem from rigorous research and a deep understanding of patient needs.
Contact Information
For inquiries regarding Pelthos Therapeutics, please reach out to the contacts below:
Investors:
Mike Moyer
LifeSci Advisors, LLC
Email: mmoyer@lifesciadvisors.com
Media:
Kellie Walsh
KWM Communications
Email: pelthos@kwmcommunications.com
Phone: (914) 315-6072
Frequently Asked Questions
What is Pelthos Therapeutics focused on?
Pelthos Therapeutics is dedicated to developing innovative therapeutic products aimed at addressing unmet patient needs.
When will the fireside chat take place?
The fireside chat is scheduled for December 4 at 9:30 a.m. Eastern Time during the Piper Sandler Annual Healthcare Conference.
How can investors participate?
Investors attending the conference can schedule one-on-one meetings with Pelthos’ CEO via their Piper Sandler representatives.
What product did Pelthos recently launch?
Pelthos launched ZELSUVMI™, a topical gel approved for the treatment of molluscum contagiosum.
How can I learn more about Pelthos Therapeutics?
For more information, you can visit the company's official website.
